PLPC™ Ecosystem
Executive Summary – Transaction Overview
(Confidential Institutional Brief – For Strategic and Financial Review)

1. Overview

PLPC™ (Phospholipoproteic Platform Complex) is a non-cellular, non-genomic, and non-pharmacodynamic immunobiologic ecosystem that redefines precision immunotherapy through structure-based immune education.
It comprises three fully validated and interoperable components:

- PLPC-DB™ – Structural Immunotherapy (core biological product)
- STIP™ – Structured Traceability & Immunophenotypic Platform (regulatory validation engine)
- PLPC-NX™ (ABIMPROSYC™) – Translational nutraceutical line (GRAS/DSHEA/EFSA-compliant)

Together, they constitute a Class A+ institutional asset, scientifically validated, regulatorily audited, and financially consolidated — ready for acquisition, licensing, or institutional integration.

2. Key Asset Highlights

Domain	Status / Description
Scientific Validation	Five Q1 peer-reviewed publications (*Cancers, Biomedicines, Biology, IJMS*), eleven Tier-1 congress presentations (*ASCO, ESMO, SITC, CAP25, BioJapan*). Mechanism of action validated ex vivo and through Real-World Evidence (>3,500 audited patients).
Regulatory Readiness	Aligned with FDA route, EMA Early-Access, and OECD NAM frameworks. Audited by Veristat (USA) and Freyr (Global) confirming 21 CFR Part 11 and CTD v3.2.2 compliance.
Intellectual Property	Three patent families (U.S., Japan, Australia). Proprietary algorithmic know-how secured within STIP™ (non-replicable).
Ethical & Logistical Edge	No animal testing, no human trial dependency, GMP manufacturing, room-temperature stability, and full digital traceability.
Transaction Readiness	Valuation confirmed (USD 0.8–1.5 B, pre-PIND; 1.8–2.2 B, post-PIND). Ownership and legal sovereignty certified by Corporate Declaration Act 2025.
Public Transparency	All core data published and indexed in PubMed and MDPI journals; due diligence archive openly accessible.

3. Validation Architecture

PLPC™ is validated through a dual-track model:

- STIP™ Ex Vivo Framework → captures immune activation, biomarker kinetics, and cytokine ratios (IL-6 / IFN-γ / IL-10) under controlled, non-invasive conditions.
- RWE (Real-World Evidence) → documents consistent patient-level immunological outcomes under medical supervision, replacing the need for early-phase clinical trials.

These two tracks converge into the CTD 5.3 structure, generating regulator-ready evidence under Good Documentation Practice (GDP) and GxP standards.

4. Asset Composition

Component	Function	Contribution to Value
PLPC-DB™	Structural immunotherapy product — trains the immune system to recognize, regulate, and remember cancer without pharmacologic toxicity.	~60 % of total valuation (USD 700–900 M).
STIP™	Regulatory platform ensuring reproducibility, traceability, and NAM alignment.	~30 % of valuation (USD 230–320 M).
PLPC-NX™	Translational nutraceutical branch for wellness, metabolism, and immune support.	~10 % of valuation (USD 90–120 M).

5. Competitive Advantage

- Non-cellular / Non-gene / Non-toxic — eliminates manufacturing, ethical, and clinical barriers of CAR-T or checkpoint therapies.
- Traceable by design — STIP™ ensures full data integrity and regulatory interoperability.
- Globally validated — spanning scientific, regulatory, and ethical domains.
- Ready for transaction — valuation, audits, and documentation already complete.
- Public due diligence — open-access evidence reduces investor risk and accelerates M&A decision-making.

6. Global Presence

OGRD Alliance operates as the governance body coordinating six international nodes:

Region	Primary Function
United States	Regulatory integration & FDA interface
Europe	Molecular design & quality assurance
Australia	Intellectual property management
Latin America	Clinical & RWE base
Dubai	Financial and institutional partnerships
Panama / Chile	GMP manufacturing & document control

7. Transaction Framework

PLPC™ is offered under a modular acquisition structure, allowing:

1. Full ecosystem acquisition (PLPC-DB™ + STIP™ + PLPC-NX™)
2. Licensing per domain (Therapeutic / Regulatory / Nutraceutical)
3. Joint Venture model for sovereign or institutional deployment

All supporting documentation — financial, regulatory, and scientific — is available in the Public Due Diligence Archive upon formal request.

📩 Request access: *ops@ogrdalliance.org*

📂 Subject: “Request – PLPC Documentation Set [Entity / Country]”

8. Valuation Summary

Total Consolidated Valuation (2025):

- Pre-PIND / Regulatory Activation: USD 0.8–1.5 Billion
- Post-PIND / Institutional Transaction: USD 1.8–2.2 Billion

Validated under independent audits (Veristat / Freyr) and certified by the Corporate Declaration Act (2025).

9. Conclusion

PLPC™ is not an experimental technology — it is a fully validated, regulatorily auditable, and acquisition-ready immunotherapy ecosystem that has completed the full scientific, legal, and financial cycle.
Its transparency, reproducibility, and independent verification position it as one of the most mature and de-risked biotech assets in precision immuno-oncology.
PLPC™ – From Discovery to Transaction.
The Future of Immuno-Oncology Is Now Measurable.

OGRD Alliance
Scientific & Regulatory Coordination Unit
ops@ogrdalliance.org
www.ogrdalliance.org
www.plpc-db.com
www.oncovix.com
www.abimprosyc.com
www.drramongutierrez.com